Health-related quality of life and economic burden of prurigo nodularis
- PMID: 34058278
- DOI: 10.1016/j.jaad.2021.05.036
Health-related quality of life and economic burden of prurigo nodularis
Abstract
Background: Prurigo nodularis (PN) is an understudied, pruritic inflammatory skin disease. Little is known about the effect of PN on quality of life and its associated economic burden.
Objective: To quantify the impact of PN on quality of life and its economic implications.
Methods: A cohort study of PN patients (n = 36) was conducted using the Health Utilities Index Mark 3 questionnaire. Control data from US adults (n = 4187) were obtained from the 2002-2003 Joint Canada/United States Survey of Health. Quality-adjusted life year loss and economic costs were estimated by comparing the Health Utilities Index Mark 3 scores of the PN patients with those of the controls.
Results: The PN patients had lower overall health performance compared to the controls, (mean ± SE, 0.52 ± 0.06 vs 0.86 ± 0.003, respectively, P < .001). In multivariable regression, PN was found to be associated with worse health performance (coefficient -0.34, 95% CI [-0.46 to -0.23]), most prominent in the pain subdomain (coefficient -0.24, 95% CI [-0.35 to -0.13]). This correlated to an average of 6.5 lifetime quality-adjusted life years lost per patient, translating to an individual lifetime economic burden of $323,292 and a societal burden of $38.8 billion.
Conclusion: These results demonstrate that PN is associated with significant quality-of-life impairment, similar to the level of other chronic systemic conditions. PN is also associated with a substantial individual economic burden, emphasizing the necessity of research on effective treatment options.
Keywords: chronic pruritus; disease burden; economic burden; epidemiology; health utility; itch; prurigo nodularis; pruritus; quality of life.
Copyright © 2021 American Academy of Dermatology, Inc. Published by Elsevier Inc. All rights reserved.
Conflict of interest statement
Conflicts of interest Dr Kwatra is an advisory board member/consultant for Abbvie, Celldex Therapeutics, Galderma, Incyte Corporation, Pfizer, Regeneron Pharmaceuticals, and Kiniksa Pharmaceuticals and has served as an investigator for Galderma, Kiniksa Pharmaceuticals, Pfizer Inc, and Sanofi. Drs Gabriel, Chavda, and Semenov and Authors Whang, Le, Khanna, Williams, Roh, Sutaria, and Choi have no conflicts of interest to declare.
Similar articles
-
The impact of prurigo nodularis on quality of life: a systematic review and meta-analysis.Arch Dermatol Res. 2021 Oct;313(8):669-677. doi: 10.1007/s00403-020-02148-0. Epub 2020 Oct 27. Arch Dermatol Res. 2021. PMID: 33108524
-
Health-Related QOL and Economic Burden of Chronic Pruritus.J Invest Dermatol. 2021 Apr;141(4):754-760.e1. doi: 10.1016/j.jid.2020.08.020. Epub 2020 Sep 14. J Invest Dermatol. 2021. PMID: 32941916
-
Disease burden and treatment satisfaction in patients with prurigo nodularis in Japan.J Dermatol. 2024 Feb;51(2):223-233. doi: 10.1111/1346-8138.17045. Epub 2023 Dec 8. J Dermatol. 2024. PMID: 38066728 Free PMC article.
-
Pathophysiology, diagnosis, and pharmacological treatment of prurigo nodularis.Expert Rev Clin Pharmacol. 2021 Jan;14(1):67-77. doi: 10.1080/17512433.2021.1852080. Epub 2020 Dec 11. Expert Rev Clin Pharmacol. 2021. PMID: 33191806 Review.
-
Prurigo nodularis: Epidemiology and clinical features.J Am Acad Dermatol. 2020 Dec;83(6):1559-1565. doi: 10.1016/j.jaad.2020.04.183. Epub 2020 May 23. J Am Acad Dermatol. 2020. PMID: 32454098 Review.
Cited by
-
Treatment With Upadacitinib in Refractory Prurigo Nodularis: A Prospective Cohort Study.Allergy Asthma Immunol Res. 2024 Sep;16(5):546-554. doi: 10.4168/aair.2024.16.5.546. Allergy Asthma Immunol Res. 2024. PMID: 39363772 Free PMC article.
-
Dupilumab improves pruritus and skin lesions in patients with prurigo nodularis: Pooled results from 2 phase 3 trials (LIBERTY-PN PRIME and PRIME2).JAAD Int. 2024 Apr 10;16:163-174. doi: 10.1016/j.jdin.2024.03.025. eCollection 2024 Sep. JAAD Int. 2024. PMID: 39006917 Free PMC article.
-
Dupilumab Therapy Modulates Circulating Inflammatory Mediators in Patients with Prurigo Nodularis.JID Innov. 2024 Apr 12;4(4):100281. doi: 10.1016/j.xjidi.2024.100281. eCollection 2024 Jul. JID Innov. 2024. PMID: 38947360 Free PMC article.
-
Comprehensive plasma cytokine and chemokine profiling in prurigo nodularis reveals endotypes in Type 2 inflammation.Sci Rep. 2024 Apr 6;14(1):8098. doi: 10.1038/s41598-024-58013-x. Sci Rep. 2024. PMID: 38582943 Free PMC article.
-
Dysregulation of the Skin-Liver Axis in Prurigo Nodularis: An Integrated Genomic, Transcriptomic, and Population-Based Analysis.Genes (Basel). 2024 Jan 23;15(2):146. doi: 10.3390/genes15020146. Genes (Basel). 2024. PMID: 38397136 Free PMC article.
MeSH terms
LinkOut - more resources
Full Text Sources
Research Materials
